Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24964008 | 0.88 | CTSD (0.38) | AR | |
| SCHEMBL6730325 | 0.88 | CTSD (0.38) | AR | |
| SCHEMBL5872369 | 0.86 | CCR2 (0.43) | AR | |
| SCHEMBL25134614 | 0.84 | PTGER3 (0.35) | ARPTGER3 | |
| SCHEMBL25006853 | 0.82 | PTGER3 (0.34) | PTGER3 | |
| SCHEMBL24113100 | 0.81 | PTGER3 (0.34) | ARPTGER3 | |
| SCHEMBL23722341 | 0.81 | — | — | |
| SCHEMBL25700220 | 0.80 | CCR2 (0.38) | ARPTGER3 | |
| SCHEMBL30009270 | 0.80 | CAPN1 (0.36) | CAPN1CTSL | |
| SCHEMBL24963632 | 0.80 | CCR2 (0.35) | PTGER3CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023180189-A1 | MPRO TARGETING ANTIVIRAL COMPOUNDS | EXSCIENTIA AI LIMITED (GB) | 2023-09-28 | — | — | WO | disclosed |
| US-11708348-B2 | Protease inhibitors for treatment of coronavirus infections | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230212116-A1 | SARS-COV-2 MAIN PROTEASE INHIBITORS | THE TEXAS A&M UNIVERSITY SYSTEM | 2023-07-06 | — | — | US | disclosed |
| US-20220144834-A1 | Chemical Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-05-12 | — | — | US | disclosed |
| US-20200255428-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-08-13 | — | — | US | disclosed |
| US-10392422-B2 | Macrocyclic broad spectrum antibiotics | RQX PHARMACEUTICALS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-10351595-B2 | — | — | 2019-07-16 | — | — | US | disclosed |
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-9145391-B2 | Bipyridylaminopyridines as Syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-09-29 | — | — | US | disclosed |
| US-8883828-B2 | 2-aminopyridine analogs as glucokinase activators | ARRAY BIOPHARMA INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20090156603-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-6680331-B2 | ADMINISTERING DIETHYL LACTAMS SUCH AS 3,3-DIETHYL-2-PYRROLIDINONE FOR INDUCING ANESTHESIA OR CONSCIOUS SEDATION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2004-01-20 | — | — | US | disclosed |
| US-20030078283-A1 | Lactam and thiolactam derivatives as anesthetic and conscious sedation agents | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2003-04-24 | — | — | US | disclosed |
| WO-2003007940-A1 | LACTAM AND THIOLACTAM DERIVATIVES AS ANESTHETIC AND CONSCIOUS SEDATION AGENTS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2003-01-30 | — | — | WO | disclosed |
| EP-0898562-B1 | HYDROXAMIC ACID DERIVATIVES FOR USE WITH THE TREATMENT OF DISEASES RELATED TO CONNECTIVE TISSUE DEGRADATION | UPJOHN CO (US) | 2003-01-22 | — | — | EP | disclosed |
| US-6066666-A | OPTIONALLY N-SUBSTITUTED 3-MONO- AND DI-SUBSTITUTED 2-PYRROLIDINONES AND THIOLACTAM ANALOGS; TREAT SEIZURES, ANXIETY, AND ENHANCING 4-AMINOBUTYRIC ACID (GABA)-INDUCED CHLORIDE CURRENTS AT GABA RECEPTOR/IONOPHORE COMPLEX | WASHINGTON UNIVERSITY (US) | 2000-05-23 | — | — | US | disclosed |
| CN-1210517-A | Hydroxamic acid derivatives for use with treatment of diseases related to connective tissue degradation | UPJOHN CO (US) | 1999-03-10 | — | — | CN | disclosed |
| US-5776959-A | Anticonvulsant and anxiolytic lactam and thiolactam derivatives | WASHINGTON UNIVERSITY (US) | 1998-07-07 | — | — | US | disclosed |
| US-5712300-A | ENZYME INHIBITOR | PHARMACIA & UPJOHN COMPANY (US) | 1998-01-27 | — | — | US | disclosed |
| US-4123438-A | Process for preparing 2-pyrrolidones | STAMICARBON, B.V. (NL) | 1978-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | PIK3R3, JAK2, JAK3 | AR 1141/4885PTGER3 236/4885MME 4848/4885 |
| US-10351595-B2 | — | MRPL21, PRSS1, PEPD | AR 3751/4885PTGER3 4664/4885MME 152/4885 |
| US-10392422-B2 | Macrocyclic broad spectrum antibiotics | MRPL21, PEPD, CTSC | AR 2887/4885PTGER3 4619/4885MME 230/4885 |
| US-20230212116-A1 | SARS-COV-2 MAIN PROTEASE INHIBITORS | ACE2, ACE, TMPRSS2 | AR 2613/4885PTGER3 3164/4885MME 35/4885 |
| US-20090156603-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | GCK, GCKR, PRKCSH | AR 4618/4885PTGER3 2521/4885MME 1685/4885 |
| US-20030078283-A1 | Lactam and thiolactam derivatives as anesthetic and conscious sedation agents | GABRD, GABRE, CCT8 | AR 4456/4885PTGER3 384/4885MME 3552/4885 |
| US-20220144834-A1 | Chemical Compounds | HAVCR2, HBS1L, HLA-B | AR 4430/4885PTGER3 4226/4885MME 334/4885 |
| US-11708348-B2 | Protease inhibitors for treatment of coronavirus infections | ACE, ACE2, TMPRSS2 | AR 1669/4885PTGER3 860/4885MME 48/4885 |
| US-20200255428-A1 | CHEMICAL COMPOUNDS | HAVCR2, HBS1L, HLA-B | AR 4430/4885PTGER3 4226/4885MME 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.